Browse Category

Pharmaceuticals News 13 January 2026 - 15 January 2026

Eli Lilly stock dips after hours as FDA seeks label change for Zepbound, traders eye obesity pill push

Eli Lilly stock dips after hours as FDA seeks label change for Zepbound, traders eye obesity pill push

Eli Lilly shares fell about 0.3% in after-hours trading Wednesday after the FDA asked drugmakers to remove suicide-risk warnings from GLP-1 weight-loss drugs. The agency found no link between the drugs and increased suicide risk. Investors are watching Lilly’s plans for its oral obesity drug, orforglipron, which could launch soon at a $150 monthly price.
Johnson & Johnson stock rises after Tecvayli trial win as JNJ eyes earnings

Johnson & Johnson stock rises after Tecvayli trial win as JNJ eyes earnings

Johnson & Johnson shares rose 2.3% to $218.55 in after-hours trading Wednesday after reporting its Tecvayli drug cut the risk of disease progression or death by 71% in a late-stage multiple myeloma trial. An independent committee recommended unblinding the study. Full results will be presented at an upcoming medical meeting. Investors await the company’s quarterly results next week.
Pfizer (PFE) stock rises as CEO calls obesity push a “Viagra”-scale bet, with earnings next in focus

Pfizer (PFE) stock rises as CEO calls obesity push a “Viagra”-scale bet, with earnings next in focus

Pfizer shares rose 2% to $25.65 Wednesday after CEO Albert Bourla said the company is “all in on obesity” and plans 10 Phase 3 trials for its Metsera compounds by 2026. Pfizer does not expect revenue growth to return until 2029 as it faces patent expirations and weaker COVID-related sales. AbbVie also announced new obesity drug plans. Novo Nordisk warned of tougher competition in 2026.
Structure Therapeutics stock jumps as Novo deal talk lifts obesity-drug names

Structure Therapeutics stock jumps as Novo deal talk lifts obesity-drug names

Structure Therapeutics (GPCR) shares surged 7.5% to $83.76 Wednesday on over 1 million shares traded, fueled by buyout speculation and renewed interest in oral obesity drugs. Novo Nordisk executives signaled openness to acquisitions, while Structure reported Phase 2b data showing its oral GLP-1 drug aleniglipron led to 11.3% placebo-adjusted weight loss at 36 weeks. Viking Therapeutics and Terns Pharmaceuticals also rose sharply.
Terns Pharmaceuticals stock jumps 10% as JPM conference puts TERN-701 back on the map

Terns Pharmaceuticals stock jumps 10% as JPM conference puts TERN-701 back on the map

Terns Pharmaceuticals shares rose 10.4% to $38.03 by midday Wednesday after the company announced 2026 targets for its chronic myeloid leukemia drug at the JPMorgan Healthcare Conference. The company plans a pivotal dose selection and an FDA meeting by mid-2026, following early trial data showing a 75% major molecular response at 24 weeks. Investors are watching for longer-term results and regulatory milestones.
Pfizer stock rises as CEO likens obesity-drug boom to Viagra ahead of Feb. 3 earnings

Pfizer stock rises as CEO likens obesity-drug boom to Viagra ahead of Feb. 3 earnings

Pfizer shares rose 1.4% to $25.51 Wednesday morning, outpacing a broader market decline. CEO Albert Bourla said the company misjudged the cash-pay obesity drug market and plans about 10 Phase 3 obesity trials in 2026. Investors are watching for Feb. 3 results and updates on late-stage trial launches. Pfizer expects no revenue growth before 2029 as it faces major patent expirations.
Eli Lilly stock slips as FDA drops suicide warning for Zepbound; traders eye orforglipron, earnings next

Eli Lilly stock slips as FDA drops suicide warning for Zepbound; traders eye orforglipron, earnings next

Eli Lilly shares fell about 0.4% Wednesday after the FDA ordered drugmakers to remove suicidality warnings from obesity drugs including Zepbound. The FDA said its review found no increased risk of suicidal thoughts with GLP-1 drugs. Investors are watching for updates on Lilly’s oral obesity pill ahead of the Feb. 4 earnings call.
Johnson & Johnson stock rises on Auris court win as talc fight and Jan. 21 earnings loom

Johnson & Johnson stock rises on Auris court win as talc fight and Jan. 21 earnings loom

Johnson & Johnson shares rose 1.9% to $217.80 by late morning Wednesday, outperforming a 1% drop in the S&P 500. Delaware’s Supreme Court threw out part of a ruling tied to Auris Health merger payments, possibly cutting damages by hundreds of millions. Legal battles over talc litigation continue. J&J’s Q4 earnings call is scheduled for Jan. 21.
Gelteq Limited stock jumps in premarket after CBD gel study; what’s next for GELS

Gelteq Limited stock jumps in premarket after CBD gel study; what’s next for GELS

Gelteq shares soared 48% to $1.23 in premarket trading after preclinical data showed its oral gel increased CBD absorption by over 22% versus an FDA-approved oil. The company said the findings could speed up its medicinal cannabis launch in Australia. The stock’s small market cap has amplified volatility. The results have not yet been tested in humans.
NRXP stock slips premarket as NRx says FDA fast-tracked ketamine bid with 70,000-patient dataset

NRXP stock slips premarket as NRx says FDA fast-tracked ketamine bid with 70,000-patient dataset

NRx Pharmaceuticals shares fell 4.3% to $2.13 in premarket trading after the FDA granted Fast Track status to its ketamine-based NRX-100 for suicidal ideation. The company plans to submit data from over 70,000 U.S. patients to support accelerated approval. Investors await further FDA feedback and updates during the San Francisco healthcare conference.
FTSE 100 climbs on miners and AstraZeneca as record gold keeps UK stocks in play

FTSE 100 climbs on miners and AstraZeneca as record gold keeps UK stocks in play

FTSE 100 rose 0.3% to 10,170.81 in mid-morning trade, led by gains in gold miners and AstraZeneca. Spot gold hit a record $4,639.42 an ounce after U.S. inflation data missed forecasts. The FTSE 250 slipped 0.3%, showing uneven momentum. Investors are watching a pending U.S. tariffs ruling and upcoming bank earnings.
GSK stock ticks up after Summit cancer-trial tie-up — what investors watch next

GSK stock ticks up after Summit cancer-trial tie-up — what investors watch next

GSK shares rose about 0.4% in early London trading after Summit Therapeutics announced a clinical trial collaboration to test ivonescimab with GSK’s experimental B7-H3 cancer drug. Patient dosing is expected to begin in mid-2026. GSK will report full-year results on Feb. 4. Senior managers recently acquired small amounts of GSK shares through company plans.
Eli Lilly stock in focus after hours as FDA moves on Zepbound label and pill race tightens

Eli Lilly stock in focus after hours as FDA moves on Zepbound label and pill race tightens

Eli Lilly shares fell 0.4% after hours to $1,077.19 as the FDA told drugmakers to remove suicide warnings from GLP-1 weight-loss drugs, including Lilly’s Zepbound. At the JPMorgan Healthcare Conference, Lilly and rivals pitched new obesity pills and longer-acting shots, with Lilly targeting a second-quarter U.S. approval for its oral drug. Amgen and Novo Nordisk highlighted new data and launches in the crowded obesity market.
KNSA stock slides 6% after Kiniksa maps out $900–$920 million ARCALYST outlook — what’s next

KNSA stock slides 6% after Kiniksa maps out $900–$920 million ARCALYST outlook — what’s next

Kiniksa shares fell 6.1% to $38.61 Tuesday after the company projected 2026 ARCALYST revenue of $900–$920 million, below the prior year’s growth rate. The drop followed an intraday low of $38.27. Wedbush raised its price target to $50, citing increased prescriber numbers and longer therapy use. Kiniksa reported $677.5 million in 2025 ARCALYST revenue and ended the year with $414.1 million in cash.
Ligand Pharmaceuticals stock slides as FDA pushes back Travere’s Filspari decision to April 13

Ligand Pharmaceuticals stock slides as FDA pushes back Travere’s Filspari decision to April 13

Ligand Pharmaceuticals shares fell 10.6% after the FDA extended its review of partner Travere’s Filspari label expansion, resetting the decision deadline to April 13. Travere shares dropped 19%. The FDA classified the latest filing as a “major amendment” but did not request new safety or manufacturing data. The broader biotech sector was little changed.
Travere Therapeutics stock slides as FDA pushes Filspari FSGS decision into April

Travere Therapeutics stock slides as FDA pushes Filspari FSGS decision into April

Travere Therapeutics shares fell 19% Tuesday after the FDA extended its review of Filspari for broader use in kidney disease, pushing the decision deadline to April 13. The stock hit an intraday low of $22.35 before recovering. Travere forecast $127 million in Q4 U.S. net product sales and ended 2025 with $323 million in cash and equivalents. Analyst Joseph Schwartz warned a formal rejection from the FDA remains possible.
Structure Therapeutics stock jumps 14% as Roche-Genentech patent deal back in focus

Structure Therapeutics stock jumps 14% as Roche-Genentech patent deal back in focus

Structure Therapeutics shares surged about 14% midday Tuesday after a recent SEC filing revealed a $100 million upfront patent license deal with Roche’s Genentech for an oral GLP-1 drug. The stock rose to $79.24, up $9.88 from Monday’s close, as investors re-evaluated obesity-drug makers during the J.P. Morgan Healthcare Conference.
1 8 9 10 11 12 34

Stock Market Today

Costco stock price retakes $1,000 — what traders are watching before Monday

Costco stock price retakes $1,000 — what traders are watching before Monday

7 February 2026
Costco closed Friday up 1.2% at $1,001.16, regaining the $1,000 level as about 2.36 million shares changed hands. January net sales rose 9.3% to $21.33 billion, with comparable sales up 7.1% and online sales surging 34.4%. Wells Fargo raised its price target to $950, maintaining a neutral rating. The next earnings call is set for March 5.
Johnson & Johnson stock price: What to watch after talc-case law firm ouster and new AFib data

Johnson & Johnson stock price: What to watch after talc-case law firm ouster and new AFib data

7 February 2026
Johnson & Johnson shares rose 0.9% to $239.99 Friday after a New Jersey appeals court disqualified Beasley Allen from state talc cases, citing improper coordination with a former J&J attorney. The ruling affects about 3,600 state lawsuits, while a related federal motion is pending. J&J also reported early 12-month pilot data for its investigational AFib device at a cardiology meeting.
Go toTop